FIVB Medical & Anti-Doping Regulations - January 2017 edition
- Adopted
- 2014/10/29
The 2017 edition of the FIVB Medical and Anti-Doping Regulations; the oldest version available in this collection.
| Publication | Fédération Internationale de Volleyball — 2017 edition |
| Structure | Medical and Anti-Doping Regulations, 2017 edition |
| Status | Superseded — replaced by the January 2021 version |
What are the Volleyball Medical and Anti-Doping Regulations?
The Medical and Anti-Doping Regulations of the Fédération Internationale de Volleyball (FIVB) bring two documents together in a single text: the medical rules for events — including the injury reporting procedure — and the anti-doping rules, which implement the World Anti-Doping Code in volleyball. The Federation may delegate part or all of doping control to a third party such as the International Testing Agency (ITA), and results management and adjudication to the Anti-Doping Division of the Court of Arbitration for Sport, but responsibility for compliance remains its own.
About the January 2017 version
Features of this version
- Two areas in one documentThe text brings together the medical rules for events and the anti-doping rules in one place.
Who this document matters to
Every doping case involving a volleyball player is decided on the basis of this text. The decisive point in a defence: liability is strict, and establishing a violation requires no proof of intent, fault or negligence on the athlete's part. The medical regulations are likewise binding on the team physician and the federation at international events.
